cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Rigel Pharmaceuticals Inc
27 own
30 watching
Current Price
$15.11
$-0.59
(-3.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
167.35M
52-Week High
52-Week High
17.30000
52-Week Low
52-Week Low
7.10000
Average Volume
Average Volume
0.06M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization167.35M
icon52-Week High17.30000
icon52-Week Low7.10000
iconAverage Volume0.06M
iconDividend Yield--
iconP/E Ratio--
What does the Rigel Pharmaceuticals Inc do?
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Read More
How much money does Rigel Pharmaceuticals Inc make?
News & Events about Rigel Pharmaceuticals Inc.
PR Newswire
1 year ago
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Feb...
PR Newswire
1 year ago
Thinking about buying stock in 180 Life Sciences, HTG Molecular, Markforged, Icecure Medical, or Rigel Pharmaceuticals? Thinking about buying stock in 180 Life Sciences, HTG Molecular, Markforged, Icecure Medical, or Rigel Pharmaceuticals? PR Newswire NEW YORK, Dec. 27, 2022 NEW YORK, Dec. 27, 2022...
PR Newswire
1 year ago
Rigel Announces Availability of REZLIDHIA (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation Rigel Announces Availability of REZLIDHIA (olutasidenib) in the U.S. for the Treatment of Adult Patients with...
PR Newswire
1 year ago
Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel Pharmaceuticals? Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel...
PR Newswire
1 year ago
Thinking about buying stock in Rigel Pharmaceuticals, Mullen Automotive, COMSovereign, Credit Suisse, or Tilray? Thinking about buying stock in Rigel Pharmaceuticals, Mullen Automotive, COMSovereign, Credit Suisse, or Tilray? PR Newswire NEW YORK, Dec. 2, 2022 NEW YORK, Dec. 2, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Rigel Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Rigel Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Rigel Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Rigel Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Rigel Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Rigel Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Rigel Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Rigel Pharmaceuticals Inc?
plus_minus_icon
What percentage is Rigel Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Rigel Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$15.11
$-0.59
(-3.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.87
$0.00 (0.00 %)
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
$18.52
$-1.06 (-5.41 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$468.01
$9.07 (1.98 %)
United Therapeutics Corporation
United Therapeutics Corporation
$356.75
$0.96 (0.27 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.87
$0.00 (0.00 %)
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
$18.52
$-1.06 (-5.41 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$468.01
$9.07 (1.98 %)
United Therapeutics Corporation
United Therapeutics Corporation
$356.75
$0.96 (0.27 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00